Last update Aug. 17, 2019
Likely Compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
C17 H25 N3 O2 S is Almotriptan Malate in Molecular formula.
Is written in other languages:C17 H25 N3 O2 S is also known as
Main tradenames from several countries containing C17 H25 N3 O2 S in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 70 | % |
Molecular weight | 470 | daltons |
Protein Binding | 35 | % |
VD | 2.6 - 2.9 | l/Kg |
pKa | 9.55 | - |
Tmax | 1.5 - 3 | hours |
T½ | 3 - 4 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Selective agonist for the vascular receptor of 5-hydroxytryptamine-1 (5-HT1, serotonin) with vasoconstrictor action at the intracranial level.
Indicated in acute migraine attack.
Oral administration in a daily dose.
Since the last update we have not found published data on its excretion in breastmilk.
Several expert authors consider its use to be safe or probably safe during breastfeeding (Hale 2019, Briggs 2017, Amundsen 2015, Duong 2010).
Its use, usually in isolated doses, makes the occurrence of adverse effects in infants unlikely (Jürgens 2009).
As there is less published data than for other drugs in the same group, safer known alternatives may be preferable, especially during the neonatal period and in cases of prematurity.